Cervavac Receives WHO Prequalification, Boosting Global HPV Vaccine Access for Low‑Income Countries

Cervavac – India's human papillomavirus vaccine received WHO prequalification, confirming it meets the agency’s safety, efficacy and quality criteria for use in national immunization programs and has been reviewed by an independent panel of experts.

World Health Organization – The prequalification opens the path for Cervavac to be purchased by United Nations agencies and eligible for inclusion in global cervical cancer prevention initiatives, expanding access beyond India.

Public Health Impact – With WHO endorsement, Cervavac could help lower cervical cancer rates in low‑ and middle‑income countries, supporting WHO’s goal to vaccinate 90 % of girls by age 15, though specific rollout plans remain to be announced.

Manufacturing Scale – The prequalification follows successful clinical trials that demonstrated Cervavac’s immunogenicity, and Indian manufacturers are preparing to scale production to meet anticipated demand from domestic immunization schedules and potential export contracts.